17,429 Shares in Atyr PHARMA INC (NASDAQ:ATYR) Bought by Alpine Global Management LLC

Alpine Global Management LLC purchased a new position in shares of Atyr PHARMA INC (NASDAQ:ATYR) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 17,429 shares of the company’s stock, valued at approximately $63,000.

Other hedge funds have also recently modified their holdings of the company. Group One Trading LLC acquired a new stake in Atyr PHARMA in the fourth quarter valued at $26,000. Alterna Wealth Management Inc. acquired a new stake in Atyr PHARMA in the fourth quarter valued at $36,000. Victory Capital Management Inc. acquired a new stake in Atyr PHARMA in the fourth quarter valued at $37,000. Raymond James Financial Inc. acquired a new stake in Atyr PHARMA in the fourth quarter valued at $39,000. Finally, XTX Topco Ltd acquired a new stake in Atyr PHARMA in the fourth quarter valued at $40,000. 61.72% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on ATYR shares. Leerink Partners started coverage on Atyr PHARMA in a report on Tuesday, February 18th. They issued an “outperform” rating and a $16.00 target price for the company. HC Wainwright reissued a “buy” rating and issued a $35.00 target price on shares of Atyr PHARMA in a report on Monday, May 19th. Finally, Leerink Partnrs raised Atyr PHARMA to a “strong-buy” rating in a report on Tuesday, February 18th. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $18.60.

Atyr PHARMA Trading Down 1.3%

NASDAQ:ATYR opened at $3.75 on Friday. The company has a market capitalization of $333.77 million, a PE ratio of -3.99 and a beta of 0.79. The company has a quick ratio of 5.41, a current ratio of 5.41 and a debt-to-equity ratio of 0.02. Atyr PHARMA INC has a 52-week low of $1.42 and a 52-week high of $4.66. The stock has a fifty day simple moving average of $3.24 and a 200-day simple moving average of $3.42.

Atyr PHARMA (NASDAQ:ATYR) last released its quarterly earnings results on Wednesday, May 7th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.02. On average, equities research analysts expect that Atyr PHARMA INC will post -0.91 earnings per share for the current fiscal year.

Atyr PHARMA Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.